




Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (Currently Amended) A compound of Formula (1):



wherein:

Cy is a group of Formula (2):



C<sub>3-7</sub>cycloalkyl or phenyl;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are hydrogen, halogen, hydroxy, amino, trifluoromethyl or nitrile and at least one of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> is halogen, trifluoromethyl or nitrile;

R<sub>6</sub> is hydrogen, optionally substituted straight-chained or branched C<sub>1-3</sub>alkyl, amino or hydroxy;

R<sub>7</sub> is hydrogen, optionally substituted straight-chained or branched C<sub>1-3</sub>alkyl, optionally substituted amino or hydroxy;

R<sub>8</sub> is hydrogen, methyl or ethyl;

R<sub>9</sub> is optionally substituted straight-chained or branched C<sub>1-6</sub>alkyl, optionally substituted straight-chained or branched C<sub>2-6</sub>alkenyl, optionally substituted straight-chained or branched C<sub>2-6</sub>alkynyl, C<sub>3-7</sub>cycloalkyl or optionally substituted phenyl;


R<sub>20</sub> is hydrogen or straight-chained or branched C<sub>1-3</sub>alkyl or R<sub>9</sub> and R<sub>20</sub> may together form C<sub>3-7</sub>cycloalkyl;

R<sub>10</sub> is hydrogen or straight-chained or branched C<sub>1-3</sub>alkyl;

R<sub>11</sub> is hydrogen, optionally substituted straight-chained or branched C<sub>1-3</sub>alkyl, -CO-N(R<sub>14</sub>)R<sub>15</sub>, carboxyl;

R<sub>12</sub> is hydroxy or -OR<sub>16</sub>;

R<sub>13</sub> is hydrogen, straight-chained or branched C<sub>1-6</sub>alkyl, straight-chained or branched C<sub>2-6</sub>alkenyl, straight-chained or branched C<sub>2-6</sub>alkynyl or a group of Formula (3):



R<sub>14</sub> and R<sub>15</sub>, which may be the same or different, are each hydrogen, optionally substituted straight-chained or branched C<sub>1-4</sub>alkyl, C<sub>3-7</sub>cycloalkyl, straight-chained or branched C<sub>1-4</sub>alkyloxy, straight-chained or branched C<sub>1-4</sub>alkylsulfonyl or a heterocyclic ring;

R<sub>16</sub> is straight-chained C<sub>1-4</sub>alkyl;

R<sub>17</sub> is hydrogen or methyl;

R<sub>18</sub> and R<sub>19</sub> together form cycloalkyl or C<sub>3-7</sub>cycloalkenyl;

X is carbonyl or methylene;

Y is carbonyl or methylene;

or a hydrate or pharmaceutically acceptable salt thereof.

2. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2); or a hydrate or pharmaceutically acceptable salt thereof.

3. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which at least one of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> is halogen and the others are hydrogen or hydroxy;

or a hydrate or pharmaceutically acceptable salt thereof.

4. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which R<sub>3</sub> is halogen or R<sub>2</sub> and R<sub>3</sub> are the same kind of halogen; or a hydrate or pharmaceutically acceptable salt thereof.

5. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which R<sub>3</sub> is halogen and R<sub>1</sub>, R<sub>2</sub>, R<sub>4</sub> and R<sub>5</sub> are hydrogen, or R<sub>2</sub> and R<sub>3</sub> are the same kind of halogen and R<sub>1</sub>, R<sub>4</sub> and R<sub>5</sub> are hydrogen; or a hydrate or pharmaceutically acceptable salt thereof.

6. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which at least one of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> is trifluoromethyl and the others are hydrogen, halogen or hydroxy; or a hydrate or pharmaceutically acceptable salt thereof.

7. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which at least one of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> is nitrile and the others are hydrogen, halogen or hydroxy; or a hydrate or pharmaceutically acceptable salt thereof.

8. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which R<sub>3</sub> is trifluoromethyl; or a hydrate or pharmaceutically acceptable salt thereof.

9. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which R<sub>3</sub> is nitrile;  
or a hydrate or pharmaceutically acceptable salt thereof.

Claims 10-12. (Canceled)

13. (Previously Presented) The compound according to claim 1, wherein R<sub>6</sub> in Formula (1) is hydrogen or methyl;  
or a hydrate or pharmaceutically acceptable salt thereof.

14. (Previously Presented) The compound according to claim 1, wherein R<sub>7</sub> in Formula (1) is hydrogen or optionally substituted amino; or a hydrate or pharmaceutically acceptable salt thereof.

15. (Previously Presented) The compound according to claim 1, wherein R<sub>8</sub> in Formula (1) is hydrogen or methyl;  
or a hydrate or pharmaceutically acceptable salt thereof.

16. (Previously Presented) The compound according to claim 1, wherein R<sub>9</sub> in Formula (1) is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl, phenyl, benzyl, para-hydroxybenzyl, cyclohexylmethyl or para-fluorobenzyl;  
or a hydrate or pharmaceutically acceptable salt thereof.

17. (Previously Presented) The compound according to claim 1, wherein R<sub>20</sub> in Formula (1) is hydrogen or methyl;  
or a hydrate or pharmaceutically acceptable salt thereof.

18. (Previously Presented) The compound according to claim 1, wherein  $R_{10}$  in Formula (1) is hydrogen or methyl; or a hydrate or pharmaceutically acceptable salt thereof.

19. (Previously Presented) The compound according to claim 1, wherein  $R_{11}$  in Formula (1) is methyl, hydroxymethyl, carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, carbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, cyclopropylcarbamoyl, tertbutylcarbamoyl, methoxycarbamoyl, methylcarbamoyl, methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl,; or a hydrate or pharmaceutically acceptable salt thereof.

20. (Previously Presented) The compound according to claim 1, wherein  $R_{12}$  in Formula (1) is hydroxy; or a hydrate or pharmaceutically acceptable salt thereof.

21. (Previously Presented) The compound according to claim 1, wherein  $R_{13}$  in Formula (1) is isopropyl, tert-butyl (tBu), 1,1-dimethylpropyl or 1,1-dimethyl-2-propenyl; or a hydrate or pharmaceutically acceptable salt thereof.

22. (Previously Presented) The compound according to claim 1, wherein in Formula (1) Cy is a group of Formula (2) in which at least one of  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$  and  $R_5$  is halogen and the others are hydrogen or hydroxy;  
 $R_6$  is hydrogen or methyl;  
 $R_7$  is hydrogen or optionally substituted amino;  
 $R_8$  is hydrogen or methyl;

R<sub>9</sub> is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl, phenyl, benzyl, para-hydroxybenzyl, para-fluorobenzyl or cyclohexylmethyl;

R<sub>20</sub> is hydrogen;

R<sub>10</sub> is hydrogen or methyl;

R<sub>11</sub> is methyl, hydroxymethyl, carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, carbamoyl, methylcarbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, cyclopropylcarbamoyl, tert-butylcarbamoyl, , methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl, or methoxycarbamoyl,;

R<sub>12</sub> is hydroxy;

R<sub>13</sub> is isopropyl, tert-butyl (tBu), 1,1-dimethylpropyl or 1,1-dimethyl-2-propenyl;

or a hydrate or pharmaceutically acceptable salt thereof.

23. (Original) The compound according to claim 1 which is selected from the group of compounds consisting of Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH<sub>2</sub>, Phe(4-Cl)-N-Me-Val-N-Me-Tyr(3-tBu)-NH<sub>2</sub>, Phe(3,4-F<sub>2</sub>)-N-Me-Val-N-Me-Tyr(3-tBu)-NH<sub>2</sub>, Phe(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH<sub>2</sub>, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHOMe, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(2-pyridylcarbamoyl)ethylamide, N-(2-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyrylamino)-3-(3-tBu-4-hydroxyphenyl)propyl)urea, N-(2-(2-(2-amino-3-(4-fluorophenylpropanoyl)-N-methylamino)-3-methyl)butyrylamino)-3-(3-tertbutyl-4-hydroxyphenyl)propyl)sulfamide, N-[2-(3-tertbutyl-4-hydroxyphenyl)-1-(methanesulfonylaminomethyl)ethyl]-2-[N-(4-fluorophenylalanyloyl)methylamino]-3-methylbutanamide, 2-((2-

amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-carbamidomethylethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-methanesulfonylmethylethylamide, 2-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butylamino)-3-(3-tBu-4-hydroxyphenyl)propanol, 2-(1-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butylamino)-2-(3-tertbutyl-4-hydroxyphenyl)ethyl)-6-methyl-4-pyrimidinone, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-oxadiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,2,4-oxadiazol-5-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(thiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-triazol-2-yl)ethylamide, Tyr(2-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH<sub>2</sub>, Tyr(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH<sub>2</sub>, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH<sub>2</sub>, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH<sub>2</sub>, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH<sub>2</sub>, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH<sub>2</sub>, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH<sub>2</sub>, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH<sub>2</sub>, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH<sub>2</sub>, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH<sub>2</sub>, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, N-Et-


Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHtBu, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH<sub>2</sub>SO<sub>2</sub>CH<sub>3</sub>, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH<sub>2</sub>Et, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH<sub>2</sub>Et, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH<sub>2</sub>Et, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHCH<sub>2</sub>OH, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHCH<sub>2</sub>OH, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHCH<sub>2</sub>OH, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH<sub>2</sub>Et, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH<sub>2</sub>Et, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH<sub>2</sub>Et, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH<sub>2</sub>OH, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH<sub>2</sub>OH, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHCH<sub>2</sub>OH, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH<sub>2</sub>Et, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH<sub>2</sub>Et, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH<sub>2</sub>Et, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHCH<sub>2</sub>OH, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHCH<sub>2</sub>OH, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHCH<sub>2</sub>OH, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHcPr, and Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHnPr Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH<sub>2</sub>iPr;  
or a hydrate or pharmaceutically acceptable salt thereof.

24. (Previously Presented) A pharmaceutical composition containing an effective amount of the compound according to claim 1 as an active ingredient and an inert pharmaceutically acceptable carrier.

25. (Previously Presented) A motilin receptor antagonist composition containing an effective amount of the compound according to claim 1 and an inert pharmaceutically acceptable carrier.

Claims 26-27. (Cancelled)

28. (Previously Presented) A compound of Formula (4):




wherein

Cy, R<sub>6</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>20</sub>, R<sub>10</sub>, R<sub>12</sub>, R<sub>13</sub>, X and Y are as defined in claim 1;

R<sub>7</sub>' is hydrogen, straight-chained or branched C<sub>1-3</sub>alkyl optionally having at least one protected substituent, amino optionally having at least one protected substituent or protected hydroxy; and

R<sub>11</sub>'' is hydrogen, optionally substituted straight-chained or branched C<sub>1-3</sub>alkyl, -CO-N(R<sub>14</sub>)R<sub>15</sub>, wherein R<sub>14</sub> and R<sub>15</sub> are as defined in claim 1, carboxyl, straight-chained or branched C<sub>1-3</sub>alkyl having a protected amino; or a hydrate or pharmaceutically acceptable salt thereof.

29. (Previously Presented) A compound of Formula (5):



wherein:


Cy, R<sub>6</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>20</sub>, R<sub>10</sub>, R<sub>12</sub>, R<sub>13</sub>, X and Y are as defined in claim 1;

R<sub>7</sub>'' is hydrogen, straight-chained or branched C<sub>1-3</sub>alkyl optionally having at least one optionally protected

substituent, amino optionally having at least one optionally protected substituent or optionally protected hydroxy; and

$R_{11}'$  is hydrogen, straight-chained or branched  $C_{1-3}$  alkyl optionally having at least one protected substituent, -CO-N( $R_{14}$ ) $R_{15}$  wherein  $R_{14}$  and  $R_{15}$  are as defined in claim 1, carboxyl or a hydrate or pharmaceutically acceptable salt thereof.

30. (Currently Amended) A compound of Formula (6):



wherein:

$R_8$  is hydrogen, optionally-substituted straight-chained or branched  $C_{1-3}$  alkyl, optionally substituted amino, or hydroxy;


$R_9$ , is optionally-substituted straight-chained or branched  $C_{1-6}$  alkyl, optionally substituted straight-chained or branched  $C_{2-6}$  alkenyl, optionally substituted straight-chained or branched  $C_{2-6}$  alkynyl,  $C_{3-7}$  cycloalkyl or optionally substituted phenyl;

$R_{20}$  is hydrogen or straight-chained or branched  $C_{1-3}$  alkyl; or  $R_9$  and  $R_{20}$  may together form  $C_{3-7}$  cycloalkyl;

$R_{10}$  is hydrogen or straight-chain or branched  $C_{1-3}$  alkyl;

$R_{12}$  is hydroxy or  $OR_{16}$ ;

$R_{13}$  is hydrogen, straight-chained or branched  $C_{1-6}$  alkyl, straight-chained or branched  $C_{2-6}$  alkenyl, straight-chained or branched  $C_{2-6}$  alkynyl or a group of Formula (3)



Wherein  $R_{17}$  is hydrogen or methyl;

$R_{18}$  and  $R_{19}$  together form cycloalkenyl or  $C_{3-7}$  cycloalkenyl; and

Y is carbonyl or methylene;

$P_1$  is hydrogen or a protecting group of amine; and

$R_{11}'''$  is hydrogen, optionally substituted straight-chained or branched  $C_{1-3}$ alkyl, carboxyl, straight-chained or branched  $C_{1-3}$ alkyl having protected amino or an optionally substituted heterocyclic ring, or  $-CO-N(R_{14})R_{15}$  wherein  $R_{14}$  and  $R_{15}$ , which may be the same or different, are hydrogen, optionally substituted straight-chained or branched  $C_{1-4}$  alkyl,  $C_{3-7}$  cycloalkyl, straight-chained or branched  $C_{1-4}$  alkoxy, straight-chained or branched  $C_{1-4}$ alkylsulfonyl or a heterocyclic ring, ~~carboxyl, straight chained or branched  $C_{1-3}$ alkyl having protected amino or an optionally substituted heterocyclic ring;~~  
or a hydrate or pharmaceutically acceptable salt thereof.

Claims 31-34. (Canceled)